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High dose vitamin  D3 empowers 
effects of subcutaneous 
immunotherapy in a grass 
pollen‑driven mouse model 
of asthma
Laura Hesse1,2, N. van Ieperen1,2, Arjen H. Petersen3, J. N. G. Oude Elberink4, 
Antoon J. M. van Oosterhout1,2 & Martijn C. Nawijn1,2*
Allergen‑specific immunotherapy (AIT) has the potential to provide long‑term protection against 
allergic diseases. However, efficacy of AIT is suboptimal, while application of high doses allergen 
has safety concerns. The use of adjuvants, like 1,25(OH)2VitD3 (VitD3), can improve efficacy of AIT. 
We have previously shown that low dose VitD3 can enhance suppression of airway inflammation, 
but not airway hyperresponsiveness in a grass pollen (GP)‑subcutaneous immunotherapy (SCIT) 
mouse model of allergic asthma. We here aim to determine the optimal dose and formulation of 
VitD3 for the GP SCIT. GP‑sensitized BALBc/ByJ mice received three SCIT injections of VitD3‑GP (30, 
100, and 300 ng or placebo). Separately, synthetic lipids, SAINT, was added to the VitD3‑GP‑SCIT 
formulation (300 nmol) and control groups. Subsequently, mice were challenged with intranasal GP, 
and airway hyperresponsiveness, GP‑specific IgE, ‑IgG1, and ‑IgG2a, ear‑swelling responses (ESR), 
eosinophils in broncho‑alveolar lavage fluid and lung were measured. VitD3 supplementation of 
GP‑SCIT dose‑dependently induced significantly enhanced suppression of spIgE, inflammation and 
hyperresponsiveness, while neutralizing capacity was improved and ESR were reduced. Addition of 
VitD3 further decreased Th2 cytokine responses and innate cytokines to allergens in lung tissue by 
GP‑SCIT. However, addition of synthetic lipids to the allergen/VitD3 mixes had no additional effect on 
VitD3‑GP‑SCIT. We find a clear, dose dependent effect of VitD3 on GP‑SCIT‑mediated suppression of 
allergic inflammation and airway hyperresponsiveness. In contrast, addition of synthetic lipids to the 
allergen/VitD3 mix had no therapeutic effect. These studies underscore the relevance of VitD3 as an 
adjuvant to improve clinical efficacy of SCIT treatment regimens.
Allergen-specific immunotherapy (AIT) is a treatment for allergic disorders that has the potential to induce 
long-term relieve from allergic symptoms and an immunological state of tolerance towards allergens. Successful 
AIT leads to reduced use of medication and improved quality of  life1,2. AIT is a unique form of therapy wherein 
allergens are administered via subcutaneous injection (SCIT) or sublingual application (SLIT)3,4. AIT has been 
shown to result in increased regulatory T cell numbers and activity, and suppression of numbers and activity of 
allergen-specific Th2 cells and type 2 innate lymphoid cells (ILC2s) and concomitant inhibition of eosinophilic 
inflammation. In addition, AIT induces a neutralizing antibody response that results in mast cell and basophil 
 desensitization3,5. Despite the ability of AIT to induce long term tolerance to allergens, AIT is not a routine treat-
ment for allergic asthma due to variable efficacy and long treatment duration. Moreover, the use of crude allergen 
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extracts with IgE-crosslinking capacity has safety  concerns6. Strategies to improve AIT regimens include alter-
native administration routes to achieve optimal antigen presentation at low levels of applied  allergens7,8, use of 
purified or recombinant allergens and or  peptides9,10, or addition of an adjuvant to enhance tolerance  induction11.
Use of adjuvants in AIT aims to increase allergen delivery to and uptake by antigen presenting dendritic 
cells (DCs) and to enhance their tolerogenic capacity. One candidate adjuvant for AIT, 1,25-dihydroxy-vitamin 
D3 (VitD3), binds to its nuclear hormone VitD3 receptor, and provides immunoregulatory properties through 
induction of tolerogenic  DCs12. VitD3 prevents DC-maturation leading to down-regulation of costimulatory 
molecules (CD40, CD80, CD86) and enhanced IL-10  production13, facilitating the generation of adaptive Treg 
 cells14. We have previously shown the successful use of VitD3 supplementation in AIT in the classical mouse 
model of ovalbumin-induced allergic airway  inflammation15 as well as in experimental SCIT and SLIT models 
of grass pollen (GP)  AIT11. Moreover, VitD3 supplementation in SCIT using house dust mite (HDM) extracts 
in a clinical study had (modest) positive effects on asthma symptom scores compared to control HDM-SCIT 
 treatment16.
Although the urgent clinical need for optimized vaccine formulations, few studies to date have been exploring 
the beneficial use of liposomes in  AIT17. Lipid bilayers encapsulating allergens form liposomes, like nanoparticles 
and act as delivery vehicle, form a depot or function as an adjuvant. One RDBPC trial in patients with allergic 
asthma treated with liposome-encapsulated HDM-extract showed promising results in inducing blocking IgG 
responses and lowered eosinophil numbers, although no safety data were reported in this  study18. In line here-
with, a murine model of HDM allergy was used to test intranasal application of liposome-adhered major allergens 
(Dermatophagoides pteronyssinus, Der p) Der p1 and Der p2, and found to be equally effective in lowering Th2 
responses but proved superior in increasing Treg cytokines, like IL-10 and TGF-β, when compared to the crude 
extract  alone19.
Due to the lipophilic nature of VitD3, simultaneous administration of both poorly water-soluble VitD3 and 
a freeze dried highly water-soluble GP-extract in an AIT mixture is not optimal. Notwithstanding, simultane-
ous delivery of VitD3 and the allergen extract in a single injection is desirable in order to tolerize the DCs 
presenting the allergens, without otherwise influencing the host immune response. Optimizing a formulation 
of the mixture of the hydrophilic allergen extract and the lipophilic VitD3 might enhance therapeutic efficacy. 
SAINT-18 (1-methyl-4-(cis-9-dioleyl)methyl-pyridinium-chlorid, SAINT) is a synthetic bio-compatible lipid 
which can form liposomal structures, and might be able to act as a carrier for VitD3 while encapsulating the 
GP  extract20. We therefore hypothesize that use of SAINT in GP-SCIT would enhance tolerance induction after 
GP-SCIT injections.
Previously, we showed that VitD3 supplementation in GP-SCIT augments induction of neutralizing anti-
body responses, and leads to enhanced suppression of eosinophilic inflammation and production of IL-10 in 
lung tissue. Therein, we used a single low dose of 10 ng VitD3, which did not augment suppression of airway 
hyperresponsiveness (AHR) by GP-SCIT, indicating that this low dose was not  optimal11. In the current novel 
study, we aim to find the optimal VitD3 dose in our GP-SCIT model for optimal suppression of all parameters of 
allergic airway disease. Here, we show for the first time that high dose VitD3 is in fact capable of reducing AHR, 
Th2 cytokine production and numbers of eosinophils in the lung. In addition, we aim to test whether use of the 
synthetic lipid SAINT in the mix of GP-SCIT extracts and VitD3 enhances suppression of parameters of allergic 
inflammation in an experimental mouse model of GP-SCIT. Herein, we clearly show a reproducible beneficial 
effect of VitD3 on the efficacy of GP-SCIT.
Materials and methods
Animals. BALB/cByJ mice (8–9 weeks-old) were purchased from Charles River (L’Arbresle, France) and bred 
in individually ventilated cages and fed a hypo-allergen GP-free diet (4 kcal/g, 25% protein, 11% fat, 47% sugars, 
5% fibers; AB Diets, Woerden, The Netherlands), which has a theoretical pre-manufacture level of 2900 IU/kg 
Vitamin D3. Due to the high sensitivity of vitamin D3 to light, air, heat and humidity, the actual level of Vitamin 
D3 might alter during manufacture. Female 7–9-week-old progeny were used for experiments (N = 8). The Insti-
tutional Animal Care and Use Committee (DEC) at the University of Groningen approved experiments under 
license number DEC6209 and all experiments were performed in accordance with relevant guidelines and regu-
lations. Similar experimental and materials descriptions can be found in previous  experiments21.
Induction of allergic asthma and treatment protocols. On experimental days 1 and 15, all mice 
received two intraperitoneal injections of 5000 standardized quality (SQ) units (5kSQ = 8 μg allergen extract of 
GP (Phleum pratense, Phl p; ALK-Abelló, Hørsholm, Denmark) adsorbed to 1.6 mg Alum (Imject Alum, Pierce, 
USA) in 100 µL Phosphate-buffered Saline (PBS, Fig. 1a,b and 4a,b).
Two weeks thereafter, SCIT was performed by three 100 µL s.c. injections, containing either saline or GP with 
or without 1α,25-dihydroxyvitaminD3 (VitD3, Sigma-Aldrich, The Netherlands). In a separate experiment, new 
freshly prepared formulations were made containing GP, VitD3 and or SAINT-18. In short, 300 nmol SAINT-
18 (stock in WFI, Water for Injection) was mixed with 300 ng VitD3 (stock in ethanol) and then 300kSQ GP 
was added all in glass vials. Of all formulations, the particle size was established using the Nanotrac Flex In-situ 
Analyzer (Microtrac, Germany) and considered suitable for injection.
Inhalation challenges were administered as droplets of 25kSQ GP in 25 μL PBS after light isoflurane anesthesia 
on days 45, 47 and 49. After 2 days, airway responsiveness was determined, and serum samples, broncho-alveolar 
lavage fluid (BALF), and lung lobes were stored for further analyses (− 80 °C). Both experiments were performed 
using different batches of rough extract grass pollen (Phleum pratense, 225; ID nr. 1031225. Batch numbers: 
Phl0035 and Phl0043 for research only)10,22.
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Early phase hypersensitivity: EST. After SCIT, an ear-swelling test (EST) was performed to evaluate the 
early phase response to GP. Herein, 10 μL of PBS is injected intradermal in the left ear as a control and 1kSQ of 
GP in 10 μL is injected in the right ear of mice under isoflurane/oxygen anesthesia. After 2 h, ear thickness was 
measured using a digimatic force-micrometer at 0.5 N (± 0.15 N, Mitutoyo, Japan) and the net GP-induced swell-
ing (Δ, in mm) was calculated by subtracting the thickness of the left ear from the right  ear22,23.
Airway responsiveness. By measuring airway resistance (R in  cmH2O s/mL) in response to intravenous 
administration of increasing doses of methacholine (Sigma-Aldrich) the airway responsiveness was assessed. 
Group Sensitisation Challenge
GP VitD
NC GP/ Alum PBS PBS
PC GP/ Alum PBS 25 kSQ
PCD GP/ Alum PBS 300 ng 25 kSQ
0 GP/ Alum 300 kSQ 25 kSQ
30 GP/ Alum 300 kSQ 30 ng 25 kSQ
100 GP/ Alum 300 kSQ 25 kSQ
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Figure 1.  Overview and immunoglobulin response after VitD3-supplemented GP-SCIT. (a) Experimental 
protocol. (b) Treatment groups. (c) Serum total IgE (ng/mL) before SCIT (white, Pre1), before challenge (grey, 
Pre2), and after challenge (black, Post). (d) Serum GP-spIgE (Arbitrary Units (AU)/mL). (e) GP-spIgG1. (f) 
GP-spIgG2a. (g) Neutralizing activity plotted as ratio of GP-spIgG1/GP-spIgE in Post-sera. (h) GP-spIgG2a/
GP-spIgE. (i) Fold induction of GP-spIgE (Post/Pre2). (c–f) mean ± SEM (n = 8). (g–i) Box-and-whiskers (min–
max). NC negative control; PC positive control; PCD PC with VitD3; 0, 30, 100, and 300 groups all contain GP 
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Next, lung compliance (C in mL/H2O) was examined as a measure of the comparative stiffness of the lung. In 
short, anesthetized mice were tracheotomized, cannulated through the jugular vein, and attached to a small ani-
mal ventilator; the FlexiVent (SCIREQ, Canada), and ventilated (280 breaths/min) with a tidal volume of 10 mL/
kg, pressure limited at 300 mmH2O. In response to increasing dosages of methacholine, the airway resistance 
was calculated from the pressure response to a 2-s pseudorandom pressure wave. In analyzing the peak resist-
ance (R) and peak compliance (C), all values with a coefficient of determination (COD)-value below 0.85 were 
excluded. Moreover, responsiveness was expressed as the effective dose (ED) of methacholine required to induce 
a resistance of 3 cmH2O s/mL  (ED3)9,22.
Evaluating inflammation in BALF. Similar as in previous methods  descriptions21, lungs were lavaged 
with 1 mL PBS containing 5% Bovine Serum Albumin (BSA, Sigma Aldrich, Zwijndrecht, The Netherlands) and 
a cocktail of protease inhibitors (Complete mini tablet; Roche, Germany), directly after AHR measurements. 
Subsequently, four lavages were performed with 1  mL non-supplemented PBS. After centrifugation (500 × g, 
4 min), the cell-free supernatant of the first mL was stored as BALF (in duplo, − 80 °C). The cells from the first 
mL were added to the cells from the 4 mL PBS lavages and counted using the Z2 coulter particle count and size 
analyzer (Beckman Coulter, Woerden, The Netherlands). Cytospin preparations of the BALF and Lung cells 
were stained with Diff-Quick (Merz&Dade, Dudingen, Switzerland) and 300 cells per cytospin were evaluated 
and differentiated into mononuclear cells (M), neutrophils (N), and eosinophils (E) by standard morphology.
Analysis of T cell responses: lung cell‑restimulation. As described  before21, the left lobes of the 
lungs were removed, minced and digested for 1.5 h at 37 °C in 2 mL of RPMI1640 (Lonza, Breda, The Nether-
lands) containing 1% Bovine Serum Albumin (BSA), 4 mg/mL collagenase-A (Roche Diagnostics, Almere, The 
Netherlands) and 0.1 mg/mL DNAse-I (Roche Diagnostics). Next, lung cells were forced though a 70 μm cell 
strainer (Falcon, Lelystad, The Netherlands), suspended in lysis buffer, washed and suspended again in 10 mL 
RPMI1640 containing 1% BSA. Total cell counts were established using the Beckman Coulter Counter Z2. Lung 
cells (5 × 105 cells/well) were cultured in RPMI1640 supplemented with 5% Fetal Calf Serum (FCS, Lonza, Breda, 
The Netherlands), 2 nM Ultra-GlutaMAX (Life Technologies, Bleiswijk, The Netherlands), 100EU penicillin, 
and 100 μg/mL streptomycin in a 96-wells plate (Greiner BioOne, Hannover, Germany) in the presence of 0 μg 
or 30 μg of GP per well. All samples were stimulated in triplicate for 120 h  (CO2 incubator, 37 °C) and the super-
natant was collected and stored (− 80 °C). ELISA determined concentrations of IL-5, IL-10 and IL-13, according 
to the manufacturer’s instructions (BD Pharmingen, San Diego, CA). The lower detection limits of the ELISAs 
were 32 pg/mL for IL-5, 10 mg/mL for IL-10, and 15 pg/mL for IL-13.
GP‑specific immunoglobulins. Similar experimental and materials descriptions can be found in previous 
 experiments21. Briefly, blood was collected in MiniCollect serum tubes (Greiner Bio-One, Alphen a/d Rijn, The 
Netherlands) at several time points via orbital puncture (pre-sera) and after the experiment via the vena cava 
inferior (post-sera, Figs. 1a and 4a). Briefly, for GP-spIgE, NUNC MaxiSorp flat-bottom 96-well plates (Sigma, 
MO) were coated with 1 μg/mL anti-mouse IgE (BD Pharmingen) in PBS (overnight, 4 °C), washed five times 
(wash buffer; PBS 0.05% Tween-20), blocked using 3% skimmed milk powder (ELK, Campina, Amersfoort, The 
Netherlands) in ELISA buffer, and sera samples (diluted 1:8 in PBS 1%BSA) were incubated for 2 h (room tem-
perature). Then, the plates were incubated with 100 μL 1:100 biotin labeled GP in PBS 1%BSA (homemade) for 
1.5 h, washed five times and incubated for 1 h with Streptavidin–Horseradish Peroxidase (1:200, R&D Sytems). 
Again plates were washed, following which SigmaFast™ OPD substrate (Sigma-Aldrich) was added and incu-
bated for 8 min. The reaction was stopped by adding 75 μL of 1.8 M  H2SO4. Optical density (OD) values were 
measured at 490 nm and analyzed using a classic logit-log transformation model.
For GP-spIgG1 and GP-spIgG2a, plates were coated using 10 μg/mL rough extract GP, blocked using 3%BSA 
in ELISA buffer, incubated with sera samples (1:300,000 for GP-spIgG1 and 1:100 for GP-spIgG2a), and labeled 
using biotinylated anti-mouse IgG1 or -IgG2a (1 μg/mL, BD Pharmingen). Concentrations were calculated 
according to the standard curve (using reference serum) and the results are expressed as arbitrary unit (AU)/mL.
Biotinylation of GP extract was performed using EZ-link Sulfo-NHS-LC-Biotin according to the manufac-
turers operating instructions (Thermo Scientific) and using a Slide-A-Lyzer cassette (3.5 K MWCO, Thermo 
scientific) for purification by dialysis  overnight23.
Cytokine levels in lung tissue. The right superior lung lobe was used for measurement of total protein 
content and a cytokine profile. First, lungs were weighed, homogenized and dissolved in Luminex buffer (weight 
to volume ratio 1:5) and the total protein content was measured using a BCA protein assay according to man-
ufacturer’s protocol (Thermo Scientific, USA). Concentrations of IL1α, IL-4, IL-5, IL-10, IL-13, IL-17, IL-33, 
IFNγ, Eotaxin (CCL11), GM-CSF, KC and MIP3α (CCL20) were measured using a multiplex Mouse Cytokine/
Chemokine Magnetic Bead Panels (MILLIPLEX Map Kit; Merck Millipore, Germany) according to manufac-
turer’s protocol. Plates were analyzed using a MAGPX1023 4002 with Luminex xMAP technology. Parts of these 
methods descriptions can also be found in a previous publication by Hesse et al.21.
Statistical analysis. All data are expressed as mean ± SEM. The Mann–Whitney U Test was used to analyze 
the results, and p < 0.05 was considered significant. Within the ELISA data, an AU-value which was more than 
three times the interquartile (IQ) range higher than the upper Q or more than three times the IQ range lower 
than the lower Q was considered to be an extreme outlier and was removed for further analysis. Within the AHR 
measurements, to compare the entire curve between groups, a generalized estimated equation (GEE) analysis 
was used, using SPSS Statistics 20.0.0.224.
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Results
High‑dose VitD3 decreases spIgE and induces neutralizing capacity. We have previously shown 
that addition of 10 ng VitD3 per injection enhanced suppression of airway inflammation by GP-SCIT11,23. Here, 
we aimed to determine the optimal dose of VitD3 supplementation in GP-SCIT needed to achieve suppression of 
both airway inflammation and AHR upon GP challenges in sensitized mice. To this end, we tested a dose range 
of VitD3 (0, 30, 100, 300 ng) in our established model for GP-SCIT23 (Fig. 1a,b). To examine whether VitD3 sup-
plementation changed the GP-SCIT-induced immunoglobulins, we measured total IgE, GP-spIgE, GP-spIgG1, 
and GP-spIgG2a in sera taken before SCIT (white, Pre1), before challenges (grey, Pre2), and after challenges 
(black, Post, Fig. 1c–f). GP-SCIT induced increased levels of total and GP-specific IgE, as well as increased levels 
of spIgG1 and sp-IgG2a in all experimental groups. After subsequent challenges, total and spIgE responses were 
blunted in all GP-SCIT groups compared to sham-treated controls (Fig. 1c,d). Although addition of VitD3 to 
GP-SCIT did not enhance spIgG2a levels, VitD3 supplementation did result in significantly increased spIgG1 
levels at all three dosages used (Fig. 1e,f).
To estimate the allergen-neutralizing capacity, the ratios of GP-spIgG1/GP-spIgE and GP-spIgG2a/GP-spIgE 
after GP-SCIT were calculated. We find significantly increased ratios in all SCIT groups when compared to 
control-treated mice (Fig. 1g,h). Moreover, addition of 300 ng VitD3 resulted in a trend towards increased neu-
tralizing capacity when compared to the unsupplemented GP-SCIT group. Finally, the fold increase of GP-spIgE 
levels induced by allergen challenges (GP-spIgE Post/Pre2) was significantly reduced in all GP-SCIT groups, 
regardless of the VitD3 dose (Fig. 1i).
VitD3 supplementation enhances suppression of ear swelling and AHR. We performed an 
ear swelling test (EST) after GP-SCIT, to evaluate the effects of VitD3 in GP-SCIT on the early-phase allergic 
response in vivo. High-dose VitD3-GP-SCIT did induce significant suppression of swelling as compared to the 
VitD3-treated positive controls, and showed a trend for suppression when compared to GP-SCIT without VitD3 
(Fig. 2a).
To test whether addition of VitD3 could also enhance GP-SCIT mediated suppression of AHR, we calculated 
the dose of methacholine required to induce a resistance of 3 cmH2O s/mL (ED3; Fig. 2b). Importantly, we 
observed a clear dose-dependent effect of VitD3 on ED3 after GP-SCIT, indicating that increased VitD3 levels 
correlated with less severe airway contraction after allergen challenge (Spearman’s rho = P < 0.05). Moreover, 
high-dose VitD3 resulted in a significant increase in ED3 when compared to GP-SCIT without VitD3.
In agreement herewith, airway resistance across the dose–response curve revealed suppression of AHR by 
all GP-SCIT groups as compared to their matched controls (Fig. 2c). The use of VitD3 in GP-SCIT resulted in a 
trend towards enhanced suppression compared to control GP-SCIT. Moreover, lung compliance was increased 
in VitD3-GP-SCIT as compared to the VitD3 supplemented controls and showed a trend towards an increase 
when compared to the unsupplemented GP-SCIT group (Fig. 2d).
To detect any effect of treatment on allergen-induced cytokines, we assessed cytokine levels in lung cell 
suspensions restimulated ex vivo with GP extract (Fig. 2e). Here, we observed that VitD3-GP-SCIT mice had 
reduced IL-5 production after ex vivo GP-stimulation. Moreover, we observed a VitD3 dose-dependent sup-
pression of IL-13 levels after grass pollen restimulation of lung cell suspensions (Spearman’s rho = P < 0.05), 
which resulted in a trend towards reduced IL-13 levels at the highest dose of VitD3 compared to GP-SCIT in the 
absence of VitD3. Restimulation of lung cell suspensions was unable to alter levels of IL-10 and IFN-γ (Fig. 2e).
VitD3 enhances suppression of eosinophilic inflammation. To evaluate suppression of airway 
inflammation, we compared cell counts of eosinophilic granulocytes and cytokine levels in lung (Fig. 3a–e). 
As expected, we found that the number of eosinophils in both BALF and lung tissue is reduced after GP-SCIT 
(Fig. 3c,d). When assessing VitD3 effects on GP-SCIT mediated eosinophil suppression, we only observed a 
trend towards enhanced suppression in lung tissue at the highest VitD3 dose as compared to GP-SCIT. To com-
pare the effect of VitD3 in GP-SCIT corrected for any possible baseline effect of VitD3 on eosinophil numbers 
in lung, we calculated fold reduction in eosinophils of both GP-SCIT groups relative to their respective controls. 
Here, we observed an enhanced suppression in eosinophil numbers in BALF and lung tissue by GP-SCIT after 
high-dose VitD3 supplementation (Fig. 3d,e).
Next, we analyzed cytokine levels in lung homogenates and observed that GP-SCIT failed to suppress levels 
of IL-4, IL-5 and IL-13 in lung tissue in the absence of VitD3. In contrast, levels of IL-4, IL-5 and IL-13 were 
suppressed by VitD3-GP-SCIT, both compared to the sham-treated and to the GP-SCIT groups (Fig. 3f). To test 
whether VitD3-GP-SCIT also affected the innate response to allergens, we assessed levels of pro-inflammatory 
chemokines and alarmins released by lung structural cells upon GP challenges. Interestingly, VitD3 in GP-SCIT 
resulted in reduced levels of eotaxin (CCL11), GM-CSF, IL-33, and KC when compared to GP-SCIT. Although 
not significant, similar results were found in IL-1α levels. No significant effects were found in levels of IL-10, 
MIP3α (CCL20), IFN-γ, and IL-17 (Suppl Fig. 1).
Unaltered immunoglobulin responses after SAINT complexed to VitD3‑GP‑SCIT. Next, we 
analyzed whether the use of the synthetic lipid SAINT as a carrier for the lipophilic VitD3 in the GP-SCIT for-
mulation could further improve the efficacy of GP-SCIT and the adjuvant effect of VitD3 (Fig. 4a,b). As in the 
previous experiments, we observed a marked increase in total and GP-spIgE and in spIgG1 and spIgG2a after 
GP-SCIT (Pre2, Fig. 4c–f), while GP-spIgE responses were blunted after challenges in all SCIT groups compared 
to their controls (Post, Fig. 4d). However, no differences were found in the spIgE levels obtained from SAINT-
VitD3-GP-SCIT groups (GP100DS and GP300DS) when compared to the GP-SCIT groups.
6
Vol:.(1234567890)
Scientific Reports |        (2020) 10:20876  | https://doi.org/10.1038/s41598-020-77947-6
www.nature.com/scientificreports/
c











































































































































NC PC PCD 0 30 100 300
SCIT
NC PC PCD 0 30 100 300
SCIT
NC PC PCD 0 30 100 300
SCIT
e











Figure 2.  Clinical manifestations after VitD3-supplemented GP-SCIT. (a) Net ear thickness (mm) two hours 
after GP injection performed after SCIT. Placebo-SCIT treated mice were plotted together as Controls (NC and 
PC). (b) Effective Dose (ED) of Methacholine, when the resistance reaches 3 cmH2O s/mL (non-parametric 
Spearman’s rho p < 0.05). (c) Airway Resistance (R in  cmH2O s/mL) and as (d) Airway Compliance (C in mL/ 
 cmH2O). (e) Net levels of IL-5, IL-10, IL-13 (non-parametric Spearman’s rho p < 0.05), and IFNγ measured in 
restimulated lung single cell suspensions. Absolute values are expressed as mean ± SEM (n = 8). NC negative 
control, PBS challenged; PC positive control, GP challenged; PCD PC with VitD3 in SCIT (300 ng); 0, 30, 100, 
and 300 groups all contain 300kSQ GP with 0, 30, 100, and 300 ng VitD3 respectively. *P < 0.05, **P < 0.01, 
***P < 0.001 compared to PC or PCD: unless otherwise specified.
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Figure 3.  The eosinophilic and cytokine response after VitD3-GP-SCIT. (a) Total cell counts in bronchoalveolar 
fluid (BALF) and lung single cell suspensions (Lung). (b) Differential cytospin cell counts in BALF and in (c) 
Lung. M mononuclear cells, E eosinophils, N Neutrophils. Box-and-whiskers plots (min–max). (d) BALF and 
lung eosinophils, both plotted as ratio of suppression (absolute EO/average PC EO; mean ± SEM). e Levels of 
IL-4, IL-5, IL-13, and eotaxin, GM-CSF, IL-1α, IL-33, and KC in pg/mg protein in lung tissue (mean ± SEM, 
n = 8). NC negative control, PBS challenged; PC positive control, GP challenged; PCD PC with VitD3 in SCIT 
(300 ng); 0, 30, 100, and 300 groups all contain 300kSQ GP with 0, 30, 100, and 300 ng VitD3 respectively. 
*P < 0.05, **P < 0.01, ***P < 0.001 compared to PC or PCD: unless otherwise specified.
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Figure 4.  Overview and immunoglobulin response after VitD3-supplemented GP-SCIT. (a) Experimental 
protocol. (b) Treatment groups. (c) Serum total IgE (ng/mL) taken before SCIT (white bars, Pre1), after SCIT 
(grey bars, Pre2), and after challenges (black bars, Post). (d) GP-spIgE (Arbitrary Units (AU)/mL, Pre1-2, 
Post). (e) GP-spIgG1 (AU/mL, Pre1-2, Post). (f) GP-spIgG2a (AU/mL, Pre1-2, Post). (g) Neutralizing activity 
plotted as ratio of GP-spIgG1/GP-spIgE in Post sera. (h) Neutralizing activity of GP-spIgG2a/GP-spIgE. (i) 
Fold induction of GP-spIgE after challenge (Post-sera/Pre2-sera). (c–f) mean ± SEM (n = 8). (g–i) Box-and-
whiskers plots (min–max). NC negative control, PBS challenged; PC positive control, GP challenged; PCS PC 
with 300 nmol SAINT; PCD PC with 300 ng VitD3 in SCIT; GP 300kSQ GP in SCIT; GPS 300kSQ + 300 nmol 
SAINT; GPD 300kSQ + 300 ng VitD3; GP100DS 300kSQ + 100 ng VitD3 + 300 nmol SAINT; GP300DS 
300kSQ + 300 ng VitD3 + 300 nmol SAINT. *P < 0.05, **P < 0.01, ***P < 0.001 compared to their own matching 
controls, unless otherwise specified.
9
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20876  | https://doi.org/10.1038/s41598-020-77947-6
www.nature.com/scientificreports/
Next, addition of VitD3 to GP-SCIT did show a trend towards increased spIgG1 and spIgG2a, when com-
pared to unsupplemented GP-SCIT (Fig. 4e,f). Although all GP-SCIT groups showed a marked increase in 
levels of neutralizing antibodies, SAINT as carrier did not result in higher spIgG1 or spIgG2a levels compared 
to VitD3-GP-SCIT.
As a measure of neutralizing capacity after GP-SCIT, the ratios of GP-spIgG1/GP-spIgE and GP-spIgG2a/GP-
spIgE after GP-SCIT were calculated. No effect of VitD3 was observed in these analyses, either with or without use 
of SAINT as a carrier, although strong induction of neutralizing capacity of spIgG1 was seen after GP challenges 
in all SCIT groups (Fig. 4g,h). Furthermore, we observed a striking decrease in fold induction of GP-spIgE levels 
by allergen challenges in all GP-SCIT groups, with a significant decrease in the VitD3 supplemented GP-SCIT 
treated group when compared to GP-SCIT alone (Fig. 4i).
SAINT mixed VitD3‑GP‑SCIT does not enhance suppression of AHR or ear swelling. Next, we 
assessed whether the effect of SAINT mixed with VitD3-GP-SCIT improves the early-phase response to intra-
dermal GP injections. Ear swelling was reduced in GP-SCIT groups as compared to their controls, and similar as 
previously; addition of VitD3 in GP-SCIT resulted in a trend towards suppression when compared to GP-SCIT 
(Fig. 5a). Addition of SAINT to the mixture did not further improve the swelling responses in the VitD3-GP-
SCIT animals.
To measure effects of SAINT and VitD3-GP-SCIT mediated suppression of AHR, we measured airway resist-
ance (R) and compliance (C) and calculated the  ED3 values (R of 3 cmH2O s/mL) (Fig. 5b–d). The ED3 values 
were significantly increased compared to controls in all experimental groups except for the high-dose SAINT-
VitD3-GP-SCIT group, however no net effect of VitD3 supplementation was found (Fig. 5b). In addition, in 
analyzing the dose–response curve of airway resistance, we observed a significant decrease in all GP-SCIT groups 
compared to the controls, and found a trend towards suppression in the VitD3-GP-SCIT group when compared 
to GP-SCIT mice (Fig. 5c). Nonetheless, addition of SAINT did not result in an increased suppression of AHR. 
For lung compliance, only the VitD3 supplemented GP-SCIT showed a significant improvement compared to 
the sham-treated positive controls (PCD), however, no effect of the use of SAINT was detected (Fig. 5d).
Restimulation of lung cell suspensions with allergen extract ex vivo to detect any allergen-induced cytokines 
revealed marked suppression of IL-5 and IL-13 production in all SCIT mice (Fig. 5e). Addition of VitD3 in 
GP-SCIT resulted in a trend towards suppression in IL-5 when compared to unsupplemented GP-SCIT mice. 
Furthermore, we observed increased IL-10 levels in these allergen recall cultures in all GP-SCIT treated groups, 
but due to high variability with the groups this was significant only for unsupplemented and VitD3-GP-SCIT 
groups, when compared to their matched controls. Addition of VitD3 did result in a trend towards increased 
IL-10 levels, when compared to GP-SCIT treated animals (Fig. 5e). Although inclusion of SAINT was unable 
to improve Th2 inflammatory status alone, VitD3 supplementation did result in augmented suppression of Th2 
cytokine production ex vivo.
Effects of SAINT on suppression of eosinophilic inflammation and cytokine responses. To 
assess effects of SAINT in VitD3-GP-SCIT on inflammation, we compared cell counts of eosinophilic granu-
locytes and levels of cytokines in lung tissue after GP-SCIT (Fig. 6a–c). We observed a marked suppression of 
eosinophil numbers in BAL fluid and lung tissue after GP-SCIT, irrespective of the use of VitD3 and SAINT 
(Fig. 6b,c). However amongst these striking results, we were unable to detect a net SAINT mediated effect on 
GP-SCIT, which was also evident when the data were presented as fold reduction in eosinophils of both GP-
SCIT treated groups relative to their matched controls (Fig. 6d,e).
Finally, we also analyzed cytokine levels in BAL fluid and observed that levels of IL-5 and IL-13 were sig-
nificantly affected by GP-SCIT, but we failed to detect additional suppression by VitD3 with or without SAINT 
(Fig. 6f). However, we were able to show a significant increase of IL-10 in the VitD3-GP-SCIT group compared 
to the matched positive controls, both in absence and presence of SAINT.
Discussion
We previously reported the capacity of VitD3 to enhance efficacy of GP-SCIT in inducing a GP-spIgG2a response, 
suppressing eosinophils and enhancing IL-10 levels in lung  tissue21. However, clinically relevant parameters such 
as airway hyperresponsiveness were not affected by VitD3 use. Therefore, in the current study, we analyzed the 
dose-dependent effects of VitD3 on GP-SCIT treatment, and we for the first time report a clear effect of high-
dose VitD3 when compared to the unsupplemented GP-SCIT group: lower total- and GP-spIgE levels and an 
enhanced GP-spIgG1 response resulting in increased neutralizing activity, as well as suppression of ear swelling 
responses and airway resistance, Th2 cytokines, and eosinophils in BALF and lung tissue (Supplemental Table 1). 
Importantly, we report a clear correlation between dose of VitD3 during GP-SCIT and ED3 after allergen chal-
lenges, which reflects the responsiveness to methacholine in the lower part of the dose–response curve. These 
data identify airway resistance as one of the most sensitive parameters to increasing dosages of VitD3. Addition 
of the synthetic, bio-compatible lipid SAINT as carrier for the lipophilic VitD3, however, did not further enhance 
the VitD3-dependent suppression of allergic manifestations, even at suboptimal GP-dosages.
Previously, we showed that VitD3 enhanced effects of SCIT in an OVA-driven mouse model for allergic airway 
 inflammation25. Herein, co-administration of 10 ng VitD3 with suboptimal OVA-SCIT enhanced suppression 
of AHR and eosinophilia, and increased levels of IL10 and TGF-β. More recently, we provided evidence that 
10 ng VitD3 used as adjuvans in GP-SCIT and GP-SLIT augments induction of neutralizing antibodies, results in 
enhanced eosinophil-suppression and IL-10 production in lung  tissue11. In the current study, we tested the dose 
dependent VitD3 effects in GP-SCIT, and show clear dose-dependent effects for some parameters only, while 
optimal suppression of the parameters of allergic airway inflammation by GP-SCIT are achieved at the highest 
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Figure 5.  Clinical manifestations after VitD3-supplemented GP-SCIT. (a) Net ear thickness (mm) 2 h after 
GP injection performed after SCIT. Placebo-SCIT treated mice were plotted together as Controls (NC and 
PC). (b) Effective Dose (ED) of Methacholine, when the airway resistance reaches 3 cmH2O s/mL. (c) Airway 
hyperactivity (AHR) was plotted as Resistance (R in  cmH2O s/mL) and as (d) Compliance (C in mL/cmH2O). 
(e) Net levels of IL-5, IL-10, IL-13, and IFNγ in restimulated lung cell suspensions. Mean ± SEM (n = 8). NC 
Negative Control, PBS challenged; PC Positive Control, GP challenged; PCS PC with 300 nmol SAINT; PCD PC 
with 300 ng VitD3 in SCIT; GP 300kSQ GP in SCIT; GPS 300kSQ + 300 nmol SAINT; GPD 300kSQ + 300 ng 
VitD3; GP100DS 300kSQ + 100 ng VitD3 + 300 nmol SAINT; GP300DS 300kSQ + 300 ng VitD3 + 300 nmol 
SAINT. *P < 0.05, **P < 0.01, ***P < 0.001 compared to their own matching controls, unless otherwise specified.
11
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20876  | https://doi.org/10.1038/s41598-020-77947-6
www.nature.com/scientificreports/
NC PC PCS PCD GP
BALF 2,5 ± 0,7 7,9 ± 1,9 10,5 ± 3,3 4,8 ± 2,1 8,5 ± 2,3
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Figure 6.  The eosinophilic and cytokine response after VitD3-GP-SCIT. (a) Total cell counts in BALF and 
Lung. (b) Differential cytospin cell counts in BALF and in (c) Lung. M mononuclear cells, E eosinophils, N 
neutrophils. (b, c) Box-and-whiskers plots (min–max). (d) BALF and (e) Lung eosinophils, both plotted as 
ratio of suppression (absolute EO/average PC EO; mean ± SEM). (f) Levels of IL-5, IL-10, and IL-13 in pg/
mL measured in BALF; mean ± SEM (n = 8). NC Negative Control, PBS challenged; PC Positive Control, GP 
challenged; PCS PC with 300 nmol SAINT; PCD PC with 300 ng VitD3 in SCIT; GP 300kSQ GP in SCIT; GPS 
300kSQ + 300 nmol SAINT; GPD 300kSQ + 300 ng VitD3; GP100DS, 300kSQ + 100 ng VitD3 + 300 nmol SAINT; 
GP300DS 300kSQ + 300 ng VitD3 + 300 nmol SAINT. *P < 0.05, **P < 0.01, ***P < 0.001 compared to their own 
matching controls, unless otherwise specified.
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dose of VitD3 (300 ng per injection). The difference in efficacy of VitD3 between the OVA and GP models (10 ng 
vs. 300 ng VitD3 per injection) most likely stems from the use of a purified protein (OVA), which has tolerogenic 
properties upon repeated  administration26 versus a natural GP extract, which contains multiple allergens and 
may be immune-stimulatory. We feel that the SCIT model using the GP extract is a better translational model 
for the clinical practice where treatment depends on the use of allergen extracts or modifications  thereof23.
In clinical studies, VitD3 insufficiency is thought to contribute to  asthma27 and supplementation of VitD3 
resulted in a reduction of the number of exacerbations in asthmatic  patients28. Generally, its mechanism of action 
involves both directing the immune system towards a tolerogenic response, and enhancing epithelial barrier 
 function29,30. Increased risk for persistent asthma in VitD deficient children may be associated with enhanced 
susceptibility to allergic  sensitization31, while VitD supplementation provides clinical improvement in atopic 
 disease32. Wolsk et al. found a reduction in the risk of recurrent wheeze and acute respiratory tract infections in 
early life after VitD3 supplementation during  pregnancy33. In addition to baseline effects on asthma susceptibil-
ity, VitD3 might also improve the response to AIT. For instance, in allergic rhinitis patients, clinical effect of 
SCIT was more pronounced in patients whose VitD serum levels were sufficient during  treatment34. In contrast, 
VitD supplementation in HDM-SCIT treated asthmatic children had no effect on symptom scores, spIgG1, nor 
regulatory cytokines IL-10 and TGF-β, although a slight increase in expression of  FOXP3+ T cells was observed 
hinting its potential as AIT-adjuvants16.
Experimental mouse models of allergic airway disease have been used to further evaluate the effect of VitD3 
levels on clinically relevant  parameters30. Similar to the clinical studies, perinatal VitD deficiency in mice has 
immunomodulatory effects such as Th2 skewing and reduced numbers IL-10+ Tregs, both exaggerated upon 
HDM  challenges35. Heine et al. showed that VitD deficiency in mice promotes allergic sensitization to OVA, while 
co-administration of 25(OH)D in OVA-SCIT reduced airway inflammation, Th2 cytokines in the lungs, and AHR 
after  challenges36. Moreover, VitD supplemented Der p2-allergoid SCIT enhanced reduction of Th2 cytokines 
and eosinophilia and induced increased numbers of  Tregs37. In our GP-SCIT mouse model, we report a similar 
suppression of Th2 activity by VitD3 supplementation. In contrast to our previous study using 10 ng VitD3, 
however, we did not observe induction of IL-10 in either lung tissue or in restimulated lung cells. Interestingly, 
we additionally observed suppression of a number of innate cytokines and chemokines in lung, including eotaxin 
(CCL11), GM-CSF, IL-33, and KC. The mechanism for this modulation of the lung innate immune response is 
unclear, but could involve enhanced induction of Treg cells after  SCIT38, due to VitD3-dependent tolerogenic 
effects on the local APC. The suppression of the innate responses in lung-resident cells might be in line with 
enhanced Treg activity, although direct, systemic effects of the locally applied VitD3 cannot be  excluded28.
Next, we tested whether use of SAINT in GP-SCIT would enhance tolerance induction after GP-SCIT injec-
tions by acting as a lipophilic carrier for VitD3. A SAINT-18 molecule contains two hydrophobic tails and 
one cationic pyridinium head group and builds complexes with the liposomal  structures20. Similar as previous 
findings using carrier formulations like chitosan and PLGA-nano particles, SAINT-18 captures allergens and 
could induce an enhanced allergen uptake and presentation. For instance, Liu et al. reported beneficial effects of 
using chitosan as a chitosan-Der f nano-vaccine in a mouse model of intranasal  AIT39. Also in a murine model, 
Saint-Lu et al. showed chitosan formulations to have mucoadhesive properties, induced enhanced uptake of OVA 
when applied sublingually and enhanced tolerance induction via lowered AHR, eosinophils, as well as specific 
Th2  responses40. More recently, PLGA-nano particles were used to enhance efficacy of SLIT in a murine model 
of allergic  rhinitis41.
The crucial determinant in the treatment efficacy might be the particle size of the new formulations. The 
smaller the particles the better the antigen uptake and presentation, and classic liposomal formulations generally 
range between 50–250 nm in size, and are unstable below 50 nm due to the high curvature this requires for the 
 lipids42,43. Moreover, smaller sized particles could possess adjuvant activity towards activation and maturation 
of DCs in a inducer of humoral and cellular  immunity44. Our SAINT/GP formulations were prepared fresh and 
prepared in a standard sequence (WFI, SAINT-18, VitD3 and as a last component GP), resulting in a stable 
formulation with acceptable particle sizes (464–474 nm; 43.9 Vol%, data not shown). However, in pilot stability 
experiments, we did find that at higher dosages of VitD3, the mixture became more emulsified, and particle size 
would decrease to 78–80 nm (71.6 Vol%), possibly leading to more efficient phagocytosis by the APCs. However, 
we show that while VitD3 improves GP-SCIT, this effect was not enhanced by use of SAINT-18 as a carrier, argu-
ing against an increased phagocytosis by the APCs.
Our study design also had some limitations, including the inclusion of VitD3 with the SCIT injections, which 
will result in local, but not systemic increases in VitD3 levels. Previously, it was found that VitD3-enriched chow 
(10,000 IU/kg) resulted in decreased AHR and airway inflammation compared to standard chow (2000 IU/
kg)45. We used a diet containing 2900 IU/kg VitD3 in all groups, while VitD3 for SCIT supplementation was 
administered in the allergen injections, thereby selectively increasing local VitD3 levels, with the aim to induce 
a tolerogenic phenotype in the DCs responsible for allergen presentation. As we also see an effect on AHR and 
airway inflammation, similar to systemic VitD3 levels, we conclude that local effects are sufficient for the VitD3-
mediated enhanced suppression of GP-SCIT.
Another limitation of our study is that not all VitD3-effects on GP-SCIT mediated suppression were observed 
in both experiments (dose-finding vs. use of SAINT as a carrier). To allow for an overall comparison between the 
two experiments, we have included a comparison of the experimental parameters between the two experiments 
in Supplemental Table 1. The VitD3 dose-finding experiment showed marked effects of VitD3 supplementa-
tion at the highest dose on most of the experimental parameters, whereas in the SAINT experiment, addition 
of VitD3 to GP-SCIT only had an effect on a subset of the experimental parameters, including the neutralizing 
antibody response, GP-induced ear swelling, and cytokine responses in lung tissue. The VitD3 effects on AHR 
and eosinophilic inflammation in GP-SCIT mice did not reach statistical significance in the SAINT experiment. 
In this respect, it is important to note that these two experiments were performed using different batches of 
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Phleum pratense extract, which might explain some differences. Notwithstanding these subtle differences between 
experiments, we clearly show a reproducible effect of VitD3 on the efficacy of GP-SCIT.
In this study, VitD3 supplementation of GP-SCIT dose-dependently induced significantly enhanced sup-
pression of spIgE, inflammation and hyperresponsiveness, while neutralizing capacity was improved and ESR 
were reduced. Addition of VitD3 further decreased Th2 cytokine responses and innate cytokines to allergens in 
lung tissue by GP-SCIT. In contrast, addition of synthetic lipid, SAINT to the GP-VitD3 mix had no therapeutic 
effect. These studies underscore the relevance of VitD3 as an adjuvant to improve clinical efficacy of SCIT treat-
ment regimens.
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